Sascha is a Co-Founder and Partner of FORTY51 Ventures, a novel venture capital fund focused on company building and early-stage investments in European biotech. Sascha has more than 25 years of experience in Pharma and Biotech. Before co-founding FORTY51 Sascha was the Head of Global Transactions at Roivant where he was a member of the company’s Investment Committee and built Roivant’s European operations. Before that he spent a successful career across different functions at the Roche/Genentech Group, including senior roles in Partnering and BD and his last role as Roche’s Deputy Global Head of M&A overseeing many of Roche’s landmark deals from start to finish. He started his career as a banker at UBS. Over the course of his career he has lead over 50 closed transactions (investments, partnering, M&A). Sascha holds an MBA from the University of Basel, is a GMP alumnus of Harvard Business School and a certified Financial Analyst (EFFAS).  He currently sits on several boards including Mosanna Therapeutics, Mysthera Therapeutics and Tarsier Pharma.